Bryce B Reeve1,2, Molly McFatrich1, Laura C Pinheiro1,2, Meaghann S Weaver3, Lillian Sung4,5, Janice S Withycombe6, Justin N Baker3, Jennifer W Mack7, Mia K Waldron8, Deborah Gibson3, Deborah Tomlinson4, David R Freyer9, Catriona Mowbray10, Shana Jacobs10, Diana Palma9, Christa E Martens1, Stuart H Gold1, Kathryn D Jackson1, Pamela S Hinds8,11. 1. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. 2. Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina. 3. Division of Quality of Life and Palliative Care, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Canada. 5. Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada. 6. Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia. 7. Dana-Farber Cancer Institute, Boston, Massachussetts. 8. Department of Nursing Research and Quality Outcomes, Children's National Health System, Washington, District of Columbia. 9. Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California. 10. Department of Oncology, Children's National Health System, Washington, District of Columbia. 11. Department of Pediatrics, George Washington University, Washington, District of Columbia.
Abstract
BACKGROUND: Adverse event (AE) reporting in oncology trials is required, but current practice does not directly integrate the child's voice. The Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) is being developed to assess symptomatic AEs via child/adolescent self-report or proxy-report. This qualitative study evaluates the child's/adolescent's understanding and ability to provide valid responses to the PRO-CTCAE to inform questionnaire refinements and confirm content validity. PROCEDURE: From seven pediatric research hospitals, children/adolescents ages 7-15 years who were diagnosed with cancer and receiving treatment were eligible, along with their parent-proxies. The Pediatric PRO-CTCAE includes 130 questions that assess 62 symptomatic AEs capturing symptom frequency, severity, interference, or presence. Cognitive interviews with retrospective probing were completed with children in the age groups of 7-8, 9-12, and 13-15 years. The children/adolescents and proxies were interviewed independently. RESULTS: Two rounds of interviews involved 81 children and adolescents and 74 parent-proxies. Fifteen of the 62 AE terms were revised after Round 1, including refinements to the questions assessing symptom severity. Most participants rated the PRO-CTCAE AE items as "very easy" or "somewhat easy" and were able to read, understand, and provide valid responses to questions. A few AE items assessing rare events were challenging to understand. CONCLUSIONS: The Pediatric and Proxy PRO-CTCAE performed well among children and adolescents and their proxies, supporting its content validity. Data from PRO-CTCAE may improve symptomatic AE reporting in clinical trials and enhance the quality of care that children receive.
BACKGROUND: Adverse event (AE) reporting in oncology trials is required, but current practice does not directly integrate the child's voice. The Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) is being developed to assess symptomatic AEs via child/adolescent self-report or proxy-report. This qualitative study evaluates the child's/adolescent's understanding and ability to provide valid responses to the PRO-CTCAE to inform questionnaire refinements and confirm content validity. PROCEDURE: From seven pediatric research hospitals, children/adolescents ages 7-15 years who were diagnosed with cancer and receiving treatment were eligible, along with their parent-proxies. The Pediatric PRO-CTCAE includes 130 questions that assess 62 symptomatic AEs capturing symptom frequency, severity, interference, or presence. Cognitive interviews with retrospective probing were completed with children in the age groups of 7-8, 9-12, and 13-15 years. The children/adolescents and proxies were interviewed independently. RESULTS: Two rounds of interviews involved 81 children and adolescents and 74 parent-proxies. Fifteen of the 62 AE terms were revised after Round 1, including refinements to the questions assessing symptom severity. Most participants rated the PRO-CTCAE AE items as "very easy" or "somewhat easy" and were able to read, understand, and provide valid responses to questions. A few AE items assessing rare events were challenging to understand. CONCLUSIONS: The Pediatric and Proxy PRO-CTCAE performed well among children and adolescents and their proxies, supporting its content validity. Data from PRO-CTCAE may improve symptomatic AE reporting in clinical trials and enhance the quality of care that children receive.
Authors: Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring Journal: Value Health Date: 2011-10-10 Impact factor: 5.725
Authors: Darren A DeWalt; Heather E Gross; Debbie S Gipson; David T Selewski; Esi Morgan DeWitt; Carlton D Dampier; Pamela S Hinds; I-Chan Huang; David Thissen; James W Varni Journal: Qual Life Res Date: 2015-02-26 Impact factor: 4.147
Authors: J J Collins; M E Byrnes; I J Dunkel; J Lapin; T Nadel; H T Thaler; T Polyak; B Rapkin; R K Portenoy Journal: J Pain Symptom Manage Date: 2000-05 Impact factor: 3.612
Authors: Robert J Klaassen; Ronald D Barr; Joanna Hughes; Paul Rogers; Ronald Anderson; Paul Grundy; S Kaiser Ali; Rochelle Yanofsky; Oussama Abla; Mariana Silva; Anne-Sophie Carret; Mario Cappelli Journal: Cancer Date: 2010-03-15 Impact factor: 6.860
Authors: Bryce B Reeve; Janice S Withycombe; Justin N Baker; Mary C Hooke; Jessica C Lyons; Catriona Mowbray; Jichuan Wang; David R Freyer; Steven Joffe; Lillian Sung; Deborah Tomlinson; Stuart H Gold; Pamela S Hinds Journal: Pediatr Blood Cancer Date: 2013-01-17 Impact factor: 3.167
Authors: Jennifer L Hay; Thomas M Atkinson; Bryce B Reeve; Sandra A Mitchell; Tito R Mendoza; Gordon Willis; Lori M Minasian; Steven B Clauser; Andrea Denicoff; Ann O'Mara; Alice Chen; Antonia V Bennett; Diane B Paul; Joshua Gagne; Lauren Rogak; Laura Sit; Vish Viswanath; Deborah Schrag; Ethan Basch Journal: Qual Life Res Date: 2013-07-20 Impact factor: 4.147
Authors: Tamara P Miller; Brian T Fisher; Kelly D Getz; Leah Sack; Hanieh Razzaghi; Alix E Seif; Rochelle Bagatell; Peter C Adamson; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2019-04-09 Impact factor: 3.167
Authors: Molly McFatrich; Jennifer Brondon; Nicole R Lucas; Pamela S Hinds; Scott H Maurer; Jennifer W Mack; David R Freyer; Shana S Jacobs; Justin N Baker; Catriona Mowbray; Mian Wang; Sharon M Castellino; Allison Barz Leahy; Bryce B Reeve Journal: Cancer Date: 2019-09-25 Impact factor: 6.860
Authors: Bryce B Reeve; Molly McFatrich; Laura C Pinheiro; David R Freyer; Ethan M Basch; Justin N Baker; Janice S Withycombe; Lillian Sung; Jennifer W Mack; Mia K Waldron; Catriona Mowbray; Diana Palma; Pamela S Hinds Journal: J Pain Symptom Manage Date: 2017-01-03 Impact factor: 3.612
Authors: Laura C Pinheiro; Molly McFatrich; Nicole Lucas; Jennifer S Walker; Janice S Withycombe; Pamela S Hinds; Lillian Sung; Deborah Tomlinson; David R Freyer; Jennifer W Mack; Justin N Baker; Bryce B Reeve Journal: Qual Life Res Date: 2017-09-06 Impact factor: 4.147
Authors: Janice S Withycombe; Molly McFatrich; Laura Pinheiro; Pamela S Hinds; Frank G Keller; Justin N Baker; Jenny W Mack; Lillian Sung; Mia K Waldron; Bryce B Reeve Journal: Qual Life Res Date: 2019-01-17 Impact factor: 4.147
Authors: Bryce B Reeve; Molly McFatrich; Jennifer W Mack; Scott H Maurer; Shana S Jacobs; David R Freyer; Janice S Withycombe; Justin N Baker; Sharon M Castellino; Li Lin; Nicole R Lucas; Pamela S Hinds Journal: J Natl Cancer Inst Date: 2020-11-01 Impact factor: 13.506